Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Reference11 articles.
1. Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice
2. Center for Drug Evaluation and Research (2023) Food and Drug Administration (FDA), Integrated Review for Pombiliti and Opfolda, Center for Drug Evaluation and Research, Silver Spring, MD.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) (2023) European Public Assessment Report – Opfolda, European Medicines Agency, Amsterdam, NL.
4. Johnson FK Kang J Mondick J Sitaraman Das S Wasfi Y Goldman M Castelli J Do HV (2022) Mechanism of action, plasma total GAA protein PK profiles, and PK/PD relationships differ between cipaglucosidase alfa/miglustat and alglucosidase alfa in patients with late-onset Pompe disease, in 18th Annual WORLD Symposium, San Diego, CA.
5. The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease